Coronary artery disease and malignancy often occur together in older adults and share several common risk factors such as smoking, excess weight, diabetes and high blood pressure. Researchers have examined the underlying molecular processes that link these two conditions, focusing on inflammation, changes in immune cell metabolism, blood clot formation and emerging approaches in cardio-oncology.
Inflammation plays a central role in both disorders. Chronic low-grade inflammation damages blood vessel walls and promotes plaque buildup in arteries while also creating conditions that support tumor growth. Immune cells release signaling molecules that sustain this inflammatory state, contributing to disease progression in both the cardiovascular system and cancerous tissues.
Immunometabolism refers to the way immune cells alter their energy use during disease. In coronary artery disease, macrophages within arterial plaques shift toward increased glucose consumption, which heightens inflammation. Similar metabolic reprogramming occurs in the tumor microenvironment, where cancer cells and surrounding immune cells compete for nutrients and produce factors that impair normal immune responses.
Thrombosis, or abnormal blood clot formation, represents another shared pathway. Patients with cancer face elevated clotting risk due to tumor-derived substances that activate platelets and the coagulation cascade. At the same time, coronary artery disease involves plaque rupture that triggers clot formation and can lead to heart attacks. These overlapping mechanisms increase the likelihood of serious cardiovascular events in individuals undergoing cancer treatment.
Cardio-oncology has emerged as a field dedicated to managing heart complications in cancer patients. New translational research aims to identify biomarkers that predict which patients are most vulnerable to both conditions. Targeted therapies that address inflammation or metabolic pathways may offer dual benefits, reducing tumor growth while protecting heart tissue.
Population studies show that individuals with coronary artery disease have a higher incidence of certain cancers, and vice versa. Shared lifestyle factors explain part of this overlap, yet molecular evidence points to direct biological interactions. Understanding these connections could lead to integrated prevention strategies and more personalized treatment plans.
Ongoing clinical trials are testing anti-inflammatory agents in patients with both diseases. Early results suggest that modulating specific immune pathways may slow plaque progression and limit cancer spread. Researchers emphasize the need for multidisciplinary care that combines cardiology and oncology expertise.
Future work will focus on refining diagnostic tools and developing drugs that target the common molecular drivers. By addressing inflammation, immunometabolism and thrombosis together, clinicians hope to improve outcomes for the growing number of patients living with these comorbid conditions.
